Long-term safety and tolerability of brexpiprazole for Japanese patients with agitation in Alzheimer's disease dementia: A multicenter, open-label study
The extended 14-week treatment with brexpiprazole 1 or 2 mg/day after 10-week treatment was generally well tolerated in Japanese patients with agitation associated with dementia due to Alzheimer's disease, and the efficacy was maintained.
Authors
- Katsuhiro Iba (ORCID: https://orcid.org/0000-0003-1521-9067)
- Naoki Hirota (ORCID: https://orcid.org/0009-0002-9634-2488)
- Masami Nakai (ORCID: https://orcid.org/0000-0001-5159-0432)
- Kaneyoshi Takahashi (ORCID: https://orcid.org/0009-0009-1858-1150)
- Yu Nakamura (ORCID: https://orcid.org/0000-0003-2866-3669)
- Naoki Mori
- Koichi Shimizu (ORCID: https://orcid.org/0009-0008-6704-6966)
- Junko Adachi
Institutions
- Otsuka (Japan) (JP)
- Kagawa University (JP)
Publication Details
- Journal
- Journal of Alzheimer s Disease Reports
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1177/25424823251334054
- Citations
- 3
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Otsuka Pharmaceutical